Generic selectors
Exact matches only
Search in title
Search in content
Post Type Selectors

AGENĀ – Agenus Inc.

Agenus Inc.
AGEN
$4.76
Name : Agenus Inc.
Sector : Healthcare
Industry: Biotechnology
Mark. Cap: $130,503,976.00
EPSttm : 29.61
finviz dynamic chart for AGEN
Agenus Inc.
$4.76
3.05%
$0.15

Float Short %

12.2

Margin Of Safety %

Put/Call OI Ratio

0.48

EPS Next Q Diff

0.81

EPS Last/This Y

12.49

EPS This/Next Y

-3.18

Price

4.76

Target Price

11.5

Analyst Recom

2.2

Performance Q

186.75

Relative Volume

3.73

Beta

1.51

Ticker: AGEN




19 items of 1

DateSymbolLastP/C OIP/C VolTotal OI
2025-06-02AGEN4.120.160.4414040
2025-06-03AGEN50.170.0314575
2025-06-04AGEN5.60.170.8415638
2025-06-05AGEN5.170.370.6320084
2025-06-06AGEN5.950.380.0720380
2025-06-09AGEN5.550.370.0521284
2025-06-10AGEN5.360.350.2421900
2025-06-11AGEN5.150.350.2021920
2025-06-12AGEN4.820.351.7322034
2025-06-13AGEN4.690.372.1722181
2025-06-16AGEN5.140.370.0422236
2025-06-17AGEN4.760.360.2022774
2025-06-18AGEN4.480.360.1622896
2025-06-20AGEN4.780.360.1222931
2025-06-23AGEN4.810.560.0512662
2025-06-24AGEN5.010.520.0313329
2025-06-25AGEN4.910.480.6814141
2025-06-26AGEN4.930.490.1014406
2025-06-27AGEN4.760.480.8714772
DateSymbolLastP/C OIP/C VolTotal OI
19 items Current Page1 of 1




19 items of 1

DateTickerPriceCurrent Quarter Growth EstimateEBIT EstimationAverage EPS Estimate Current Year
2025-06-02AGEN4.1171.089.5-0.22
2025-06-03AGEN5.0071.089.4-0.22
2025-06-04AGEN5.6071.089.6-0.22
2025-06-05AGEN5.1671.090.2-0.22
2025-06-06AGEN5.9671.0171.81.55
2025-06-09AGEN5.55123.6161.51.55
2025-06-10AGEN5.37123.6163.21.55
2025-06-11AGEN5.15123.6162.81.55
2025-06-12AGEN4.82123.6161.51.55
2025-06-13AGEN4.71123.6163.71.88
2025-06-16AGEN5.13153.7168.51.90
2025-06-17AGEN4.76153.7161.01.90
2025-06-18AGEN4.47153.7161.81.90
2025-06-20AGEN4.78153.7167.61.90
2025-06-23AGEN4.80153.7164.91.90
2025-06-24AGEN5.01153.7166.51.90
2025-06-25AGEN4.91153.7163.81.90
2025-06-26AGEN4.93153.7164.91.90
2025-06-27AGEN4.76153.7163.11.90
DateTickerPriceCurrent Quarter Growth EstimateEBIT EstimationAverage EPS Estimate Current Year
19 items Current Page1 of 1




18 items of 1

DateTickerInsider TransactionsInstitutional TransactionsFloat Short
2025-06-02AGEN0.0012.4615.47
2025-06-03AGEN0.0012.4615.47
2025-06-04AGEN0.0012.4615.47
2025-06-05AGEN0.0012.4615.47
2025-06-06AGEN0.0012.4615.47
2025-06-09AGEN0.0012.2515.48
2025-06-10AGEN0.0012.2515.48
2025-06-11AGEN0.0012.2514.66
2025-06-12AGEN0.0012.2514.66
2025-06-13AGEN0.0012.2514.66
2025-06-16AGEN0.0012.2414.66
2025-06-18AGEN0.0012.2414.66
2025-06-20AGEN0.0012.2414.66
2025-06-23AGEN0.0012.2414.66
2025-06-24AGEN0.0012.2414.66
2025-06-25AGEN0.0012.2414.66
2025-06-26AGEN0.0012.2412.20
2025-06-27AGEN0.0012.2412.20
DateTickerInsider TransactionsInstitutional TransactionsFloat Short
18 items Current Page1 of 1

Last Quarter Act. EPS​

-1.03

Avg. EPS Est. Current Quarter

1.35

Avg. EPS Est. Next Quarter

-0.22

Insider Transactions

Institutional Transactions

12.24

Beta

1.51

Average Sales Estimate Current Quarter

49

Average Sales Estimate Next Quarter

24

Fair Value

Quality Score

50

Growth Score

29

Sentiment Score

46

Actual DrawDown %

96.4

Max Drawdown 5-Year %

-98.8

Target Price

11.5

P/E

Forward P/E

4.74

PEG

P/S

1.31

P/B

P/Free Cash Flow

EPS

-8.68

Average EPS Est. Cur. Y​

1.9

EPS Next Y. (Est.)

-1.28

Target Price Estimates Raised

Target Price Estimates Lowered

Profit Margin

-191.72

Relative Volume

3.73

Return on Equity vs Sector %

31.9

Return on Equity vs Industry %

49.8

EPS 1 7Days Diff

2.1

EPS 1 30Days Diff

7.49

EBIT Estimation

163.1
Agenus Inc.
Sector: Healthcare
Industry: Biotechnology
Employees: 316
Agenus Inc., a clinical-stage biotechnology company, discovers and develops therapies to activate the body's immune system against cancer and infections in the United States and internationally. It offers Retrocyte Display, an antibody expression platform for the identification of fully human and humanized monoclonal antibodies; and display technologies. It develops QS-21 Stimulon adjuvant, a saponin-based vaccine adjuvant. The company also develops Balstilimab, a programmed death receptor-1 (PD-1) blocking antibody; AGEN1181, a human Fc-enhanced cytotoxic T-lymphocyte antigen 4 (CTLA-4) blocking antibody that is in Phase 2 trials in metastatic colorectal cancer (mCRC), pancreatic cancer, and melanoma; AGEN2373, a CD137 monospecific antibody that is in Phase 1b clinical trial; AGEN1423, a CD73/TGFß TRAP antibody; AGEN1571, an ILT2 monospecific antibody that is in clinical development; and BMS-986442, a TIGIT bispecific antibodies. In addition, it develops INCAGN1876, a GITR agonist; INCAGN2390, a TIM-3 monoclonal antibodies; INCAGN2385, a LAG-3 monospecific antibody; MK-4830, a monospecific antibody targeting ILT4 that is in Phase 2 clinical trial; UGN-301, a zalifrelimab intravesical solution for the treatment of cancers of the urinary tract t; and AGEN1884. The company operates under the Agenus, MiNK, Prophage, Retrocyte Display, and STIMULON trademarks. It has collaborations with Bristol-Myers Squibb Company, Betta Pharmaceuticals Co., Ltd., UroGen Pharma Ltd., Gilead Sciences, Inc., Incyte Corporation, and Merck Sharp & Dohme. The company was formerly known as Antigenics Inc. and changed its name to Agenus Inc. in January 2011. Agenus Inc. was founded in 1994 and is headquartered in Lexington, Massachusetts.
stock quote shares AGENĀ – Agenus Inc. Stock Price stock today
news today AGENĀ – Agenus Inc. stock forecast ,stock prediction 2023 2024 2025
marketwatch AGENĀ – Agenus Inc. yahoo finance google finance
stock history AGENĀ – Agenus Inc. invest stock market
stock prices AGEN premarket after hours
ticker AGEN fair value insiders trading